TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01503918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir/Aciclovir
Description: 2g valaciclovir, four times a day, enterally for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Those unable to receive enteral drugs will receive intravenous aciclovir 10mg/kg three times a day. Dosing modified in the presence of renal dysfunction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir/Ganciclovir
Description: 450mg valganciclovir, once a day, by enteral route. Treatment will continue for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Intravenous ganciclovir 2.5mg/kg once a day will be used if drugs cannot be given enterally. Treatment dosing will be modified for renal dysfunction
Study: NCT02578316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Study phase dosing: participants received an initial single dose of radiolabelled 14C-lenvatinib oral patient dosing solution containing 24 mg of lenvatinib as anhydrous free base and radioactivity of 3.7 millibecquerel (MBq) on Day 1.~Extension phase dosing: 24 mg of 14C-lenvatinib: 2 x 10mg, and 4 x 1mg or 1 x 4mg tablets once-daily, continuously in each 28-day cycle during extension phase.
Study: NCT02901314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: on-demand audio messages of heart failure education themes
Study: NCT02706340

Intervention type: OTHER
Intervention: No intervention - observational study only

Intervention type: OTHER
Intervention: No intervention - observational study only
Study: NCT02539719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-003 in combination with ABBV-181
Study: NCT04585672

Intervention type: OTHER
Group type: OTHER
Intervention: Ammonia infusion
Description: Ammonia metabolism investigated in healthy individuals and patients with cirrhosis with and without ammonia lowering agent: glycerolphenylbutyrat (healthy) and Lactulose + Rifaximin (Cirrhosis)
Study: NCT01115517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg/mL applied one time intraoperatively using bevacizumab-soaked filter paper manually applied to bare sclera during pterygium surgery for 2 minutes, followed by copious rinsing with balanced salt solution.
Study: NCT01844440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High resolution manometry
Description: Subjects will undergo impedance / manometry recording with solid-state catheter systems, during a 30-min fasting and a 2-hour postprandial periods.
Study: NCT03268902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Oral Liquid Product
Description: Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
Study: NCT02137616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: Risperdal tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: quetiapine tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole tablets
Study: NCT02107261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxin A
Description: Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxin A
Description: Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT00709098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iloprost
Description: Iloprost 5 mcg delivered by I-neb(R) adaptive aerosol delivery (AAD)(R) System power disc-6 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost
Description: Iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
Study: NCT00359658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolon
Description: prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolatmofetile
Description: Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml
Study: NCT02431273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF IVR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF-FTC IVR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF-FTC-MVC IVR
Study: NCT00868504

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02269475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3250
Description: MEDI3250

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04877340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needle punction
Description: EUS-guided sampling of pancreatic solid lesions obtained with the 22-gauge

Intervention type: DEVICE
Group type: OTHER
Intervention: needle punction
Description: EUS-guided sampling of pancreatic solid lesions obtained with the 22-gauge
Study: NCT03074617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LTE field
Description: electromagnetic field of the latest standard in mobile communication (long term evolution, LTE)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham field
Description: no electromagnetic field
Study: NCT00558454

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron
Description: Ferrous succinate mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: Ferrous succinate mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: Ferrous succinate mixture
Study: NCT02222493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06438179
Description: PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
Study: NCT00468156

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: written materials only
Description: related to fruit/vegetable servings/day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: written materials
Description: related to fruit/vegetable servings/day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone support
Description: related to fruit/vegetable servings/day
Study: NCT03563690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment1
Description: 1. Acupoints：Liangqiu（ST34）,Xuehai（SP10）,Neixiyan（EX-LE4）,Dubi(ST35),Yanglingquan (GB34)and Yinlingquan (SP9)~2. operation: the needles will be manipulated using techniques including lifting, thrusting, twisting, and rotating, until De Qi is achieved for 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment2
Description: 1. Acupoints：Needling points are the same to the above group~2. operation: The electrode will be connected Neixiyan (EX-LE4) and Dubi (ST35) and electrode wire will be connected to the electro-acupuncture apparatus using dilatational wave with a frequency of 2/100 Hz, the current intensity is within participants'tolerance, for 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment3
Description: 1. Acupoints：treating points are the same to the above group~2. Operation: During treatment, participants will choose to sit with knee buckling natural 90 degrees ,with the affected knee(s) exposed. Mild moxibustion are applied at the distance of 2-3 cm away from the skin of both the Neixiyan (EX-LE4) and Dubi (ST35) for 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment4
Description: 1. Acupoints：Needling points are the same to the above group~2. Operation: Warm-needling acupuncture are applied at both Neixiyan (EX-LE4) and Dubi (ST35). That is to insert one zhuang(about 2cm)of Huai Qing Ai on the top of the needle, and burn the moxa at the lower end ,each acupoint applied 2 Zhuang for 30 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: treatment5
Description: 1. points：Sham Liangqiu（ST34）,Sham Xuehai(SP10), Sham Neixiyan(EX-LE4), Sham Yanglingquan(GB34),Sham Yinlingquan (SP9)~2. Operation: Sham acupuncture with non-meridian and non-acupoint needling method, respectively acupuncture 1cm away lateral to the above sham acupoints with a 0.18 \* 25mm single-use needle with the depth of 1-2mm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex
Description: Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib
Study: NCT00145470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine fast dissolving SL tablets 5 and 10 mg; starting dose 5 mg BID on Day 1; 5-10 mg BID after Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo fast dissolving SL tablets, BID
Study: NCT00032435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAL-40 Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAL-40 Placebo
Study: NCT00684242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg by mouth daily
Study: NCT02629679

Intervention type: BEHAVIORAL
Intervention: Regular scholastic system and organized sports
Description: This group will consist of children involved in regular school system who at the same time participate in organized sport in sport-clubs

Intervention type: BEHAVIORAL
Intervention: Regular scholastic system and organized sports
Description: This group will consist of children involved in regular school system who at the same time participate in organized sport in sport-clubs

Intervention type: BEHAVIORAL
Intervention: Regular scholastic system
Description: The group will consist of children who are regularly in school, but not being involved in organized sport activities

Intervention type: BEHAVIORAL
Intervention: Regular scholastic system
Description: The group will consist of children who are regularly in school, but not being involved in organized sport activities
Study: NCT04693949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAC
Description: Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: APA
Description: Air-borne particle abrasion of zirconia RBFDPs prior to bonding
Study: NCT02378649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator concomitant with best practice usual care
Study: NCT05370287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen inhalation
Description: Subjects will breath 100% oxygen through a mask.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen inhalation
Description: Subjects will breath 100% oxygen through a mask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging
Description: Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
Study: NCT05370287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging
Description: Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging
Description: Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging
Description: Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging
Description: Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
Study: NCT02460393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humanized TNFα monoclonal antibody
Description: Subcutaneous injection of different doses for healthy people~Subcutaneous injection of different doses in healthy people
Study: NCT01115517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Mitomycin C 0.02% will be applied to bare sclera during pterygium surgery using a medication-soaked filter paper for a duration of two minutes. After medication administration, the ocular surface will be copiously irrigated with balanced salt solution.
Study: NCT04587921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital oximeter monitoring
Description: Digital oximeter and cardiac frequency monitoring.
Study: NCT00412113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate
Description: Amlodipine besylate 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/atorvastatin calcium single pill combination
Description: Amlodipine/atorvastatin single pill combination 10/20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate
Description: Amlodipine besylate 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/atorvastatin calcium single pill combination
Description: Amlodipine/atorvastatin single pill combination 5/20 mg
Study: NCT00741806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GHB04L1
Description: single dose intranasal administration of GHB04L1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SPGN buffer
Study: NCT02657434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants received IV infusion of 1200 mg atezolizumab on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants received IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period with doses calculated using Calvart formula.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Participants received IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period with doses calculated using Calvart formula.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants received IV infusion of 75 mg/m\^2 cisplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Participants received IV infusion of 75 mg/m\^2 cisplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period.
Study: NCT02460393

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous injection of different doses for healthy people
Study: NCT00533494

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physician feedback (A)
Description: Feedback information to physicians

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physician feedback (A)
Description: Feedback information to physicians
Study: NCT02481466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portfolio diet and structured exercise
Description: Diet: Foods will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: A program encouraging 150 minutes of exercise, based on the Quebec Heart and Lung Institute exercise program. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending on goals and tolerance). The target goal will be at least 10,000 steps daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH-like diet and structured exercise
Description: Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: A physical activity/exercise program encouraging 150 minutes of exercise, based on the exercise program developed at the Quebec Heart and Lung Institute. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to develop and support a plan that aims to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending of goals and tolerance) in keeping with maximum achievable goals of participants. The target goal will be at least 10,000 steps daily recorded on their pedometers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portfolio diet and routine exercise
Description: Diet: Foods on the dietary portfolio plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g peanuts or equivalent of tree nuts/1000 kcal (Table 1A) and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist.
Study: NCT03994601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Specified dose on specified days
Study: NCT01103726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 1 and 5 mg tablets, 6 mg single dose
Study: NCT02481466

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH-like diet and routine exercise
Description: Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist.
Study: NCT02339519

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA CLASSIC
Description: Classic LMA consists of a mask with a surrounding inflatable bag compatible to the shape of the hypopharynx and a tube that has a 30° angle with a mask.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA FASTRACH
Description: Fastrach LMA has similar features to the LMA Classic, but it is designed to provide upper airway during intubation via blind intubation or fiberoptic assistance. It has a rigid handle that allows one-handed insertion, removal or adjustment.
Study: NCT01103726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: matching placebo tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 1 mg tablets, 3 mg single dose
Study: NCT03268902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide Oral Suspension
Description: Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide Oral Suspension
Description: Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
Study: NCT02339519

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA SUPREME
Description: Supreme LMA is a novel, sterile, single use, new generation supraglottic airway device which provides more rapid and higher volume gas passage through airway and can be inserted in a rapid and safe manner.